BCM
TENX icon

Boone Capital Management’s Tenax Therapeutics TENX Stock Holding History

Boone Capital Management’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-200,000
Closed -$3.2M – 20
2026
Q1 		$3.2M Buy
+200,000
New +$2.71M 0.98% 13

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Boone Capital Management's TENX Position: Q2 2026 in Review

Boone Capital Management sold out of Tenax Therapeutics (TENX) in Q2 2026, closing a stake of 200,000 shares — an estimated $3.2M sold.

Boone Capital Management first reported a position in TENX in Q1 2026 and held it in 1 quarter. The position peaked at $3.2M in Q1 2026. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • Boone Capital Management reported no remaining Tenax Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Boone Capital Management sold 200,000 Tenax Therapeutics shares in Q2 2026, an estimated $3.2M.
  • Boone Capital Management first reported a position in Tenax Therapeutics in Q1 2026 and held it in 1 quarter.
  • Boone Capital Management's Tenax Therapeutics position peaked at $3.2M in Q1 2026.
  • 111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Boone Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.